{'fraction_non_alphanumeric': 0.024054982817869417, 'fraction_numerical': 0.006872852233676976, 'mean_word_length': 6.109756097560975, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Changes in serum osteocalcin and bone‐specific alkaline phosphatase are associated with bone pain in donors receiving granulocyte–colony‐stimulating factor for peripheral blood stem and progenitor cell collection

BACKGROUND: Granulocyte–colony‐stimulating factor (G–CSF) has been used to increase the number of CD34+ peripheral blood stem and progenitor cells collected by apheresis for use in autologous or allogeneic progenitor cell transplantation. The most frequent side effect of G–CSF treatment is bone pain, which occurs in over 80 percent of healthy progenitor cell donors.